SAMSUNG PHARMACEUTICAL.CO.,Ltd.
Financials
Valuation Metrics
SAMSUNG PHARMACEUTICAL.CO.,Ltd.'s Market Cap is ₩1158B. At end of 2025 it was ₩1441B. Ranked #1125 of 2,410 in KR market (top 47%), #540 of 779 on KOSPI (top 69%), #130 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 115.82B KRW | KR#1,125/2,410 Sec#130/231 |
| Revenue | 42.74B KRW | KR#1,872/2,410 Sec#133/231 |
| Net Income | -137.15B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 121.07B KRW | KR#1,648/2,410 Sec#131/231 |
| Net Assets | 72.26B KRW | KR#1,657/2,410 Sec#139/231 |
| Employees | 86 | KR#1,753/2,410 Sec#140/231 |
| Value | ||
| P/B | 1.60x | KR#1,849/2,410 Sec#132/231 |
| P/S | 2.71x | KR#1,972/2,410 Sec#118/231 |
| FCF Yield | -8.72% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -189.80% | KR#2,368/2,410 Sec#225/231 |
| Op. Margin | -37.80% | KR#2,192/2,410 Sec#157/231 |
| Revenue Growth | -2.43% | KR#1,647/2,410 Sec#160/231 |
| Earnings Growth | -234.71% | KR#1,252/2,410 Sec#87/231 |
| Financial Health | ||
| Debt Ratio | 67.55% | KR#1,187/2,410 Sec#144/231 |
| Total Debt | 22.41B KRW | KR#1,332/2,410 Sec#107/231 |
| FCF | -10.10B KRW | KR#1,701/2,410 Sec#150/231 |
| Cash | 4.56B KRW | KR#2,030/2,410 Sec#190/231 |
| Current Ratio | 0.77x | KR#1,965/2,410 Sec#192/231 |
| Performance | ||
| 1Y Return | -19.90% | KR#1,131/2,410 Sec#77/231 |
| 1M Return | -14.31% | KR#1,038/2,410 Sec#103/231 |
| From 52W High | -47.07% | KR#1,058/2,410 Sec#77/231 |
| 1Y MDD | -46.61% | KR#806/2,410 Sec#61/231 |
| Trading | ||
| Volume | 210,695 shares | KR#357/2,410 Sec#35/231 |
| Trading Value | 256.3M KRW | KR#1,097/2,410 Sec#122/231 |
| Foreign Own. | 3.04% | KR#1,277/2,410 Sec#117/231 |
| Per Share | ||
| EPS | -1,457 KRW | KR—/2,410 Sec—/231 |
| BPS | 767 KRW | KR#2,342/2,410 Sec#219/231 |
Company Info
Samseong Pharmaceutical was founded as Samseong Pharmaceutical Office in 1929, incorporated in 1954, and listed on the KOSPI market in 1975. The company operates in pharmaceutical manufacturing and sales, bio business, and health food sales, holding 11 affiliated companies including its largest shareholder, GemVax & KAEL Co., Ltd. It markets over 80 product groups of specialized prescription drugs, such as antibiotics and prostate treatment drugs, via CSO marketing. Over-the-counter drugs like Kkasmyeongsu and Panto-A are supplied to pharmacies and convenience stores through an exclusive agreement with Jeil Health Science. Samseong Pharmaceutical is headquartered in Hwaseong, Gyeonggi Province.